Search Results - Jan P. Sutter

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease by Lorenz Kocheise, Lorenz Kocheise, Ignazio Piseddu, Ignazio Piseddu, Joscha Vonderlin, Joscha Vonderlin, Eric T. Tjwa, Eric T. Tjwa, Gustav Buescher, Gustav Buescher, Lucy Meunier, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Francesca Fianchi, Jérôme Dumortier, Jérôme Dumortier, Mar Riveiro Barciela, Mar Riveiro Barciela, Tom J. G. Gevers, Tom J. G. Gevers, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Maria-Carlota Londoño, Sona Frankova, Sona Frankova, Thomas Roesner, Vincent Joerg, Vincent Joerg, Constantin Schmidt, Constantin Schmidt, Fabian Glaser, Fabian Glaser, Jan P. Sutter, Jan P. Sutter, Thorben W. Fründt, Thorben W. Fründt, Ansgar W. Lohse, Ansgar W. Lohse, Samuel Huber, Samuel Huber, Johann von Felden, Johann von Felden, Marcial Sebode, Marcial Sebode, Kornelius Schulze, Kornelius Schulze

Get full text

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease by Lorenz Kocheise, Lorenz Kocheise, Ignazio Piseddu, Ignazio Piseddu, Joscha Vonderlin, Joscha Vonderlin, Eric T. Tjwa, Eric T. Tjwa, Gustav Buescher, Gustav Buescher, Lucy Meunier, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Francesca Fianchi, Jérôme Dumortier, Jérôme Dumortier, Mar Riveiro Barciela, Mar Riveiro Barciela, Tom J. G. Gevers, Tom J. G. Gevers, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Maria-Carlota Londoño, Sona Frankova, Sona Frankova, Thomas Roesner, Vincent Joerg, Vincent Joerg, Constantin Schmidt, Constantin Schmidt, Fabian Glaser, Fabian Glaser, Jan P. Sutter, Jan P. Sutter, Thorben W. Fründt, Thorben W. Fründt, Ansgar W. Lohse, Ansgar W. Lohse, Samuel Huber, Samuel Huber, Johann von Felden, Johann von Felden, Marcial Sebode, Marcial Sebode, Kornelius Schulze, Kornelius Schulze

Get full text

Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis by Beibei Liu, Marianne R. Spalinger, Annalisa Invernizzi, Eike Gerdes, Babett Steglich, Marlene Schwarzfischer, Andres Machicote, Penelope Pelczar, Doris Pöhlmann, Mikolaj Nawrocki, Marius Böttcher, Ayob Aleko, Lis Noelia Velasquez, Sandra Wende, Franziska Stallbaum, Justus Neuendorff, Saskia Grosshauser, Franziska Muscate, Gemma Douilhet, Laura Garcia Perez, Morsal Sabihi, Katharina Möller, Florian Viehweger, Jan P. Sutter, Christoph Kilian, Yogesh Kumar, Thorben Fründt, Guido Sauter, Thomas Rösch, Nicola Gagliani, Amedeo Caflisch, Michael Scharl, Samuel Huber

Get full text

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab by Lorenz Kocheise, Jan Kempski, Yunhe Tang, Lorenz Balcar, Victoria Berger, Miriam Tomczak, Joao Gorgulho, Ramsha Masood, Franziska Giehren, Constantin Schmidt, Jan P. Sutter, Thorben W. Fruendt, Francesca Pagani, Sophie Wulf, Julian Kött, Saskia Domanig, Anastasios Giannou, Tanja Bedke, Jöran Lücke, Tao Zhang, Siwen Zhang, Andres Machicote, Ansgar W. Lohse, Marianna Alunni-Fabbroni, Jens Ricke, Najib Ben Khaled, Matthias Pinter, Bernhard Scheiner, Samuel Huber, Johann von Felden, Ignazio Piseddu, Kornelius Schulze

Get full text